EGIE3: What Happened to Engie Brasil Stock — Q3 2026 Earnings Explained Relevance8,0
Intermediate PTENES

EGIE3: What Happened to Engie Brasil Stock — Q3 2026 Earnings Explained

Revenue and EBITDA rose in the third quarter, but net income declined—and two off-balance-sheet risks are weighing heavier than the numbers themselves.

EGIE3 shares continue to trade normally on the B3. What happened is this: Engie Brasil Energia released its third-quarter 2026 earnings on November 10—showing growing revenue and EBITDA, but falling net income—and the market used the release to price in risks that have accumulated throughout the year: rising renewable energy curtailment and ANP's decision to wipe out the regulatory asset base of Transportadora Associada de Gás (TAG). The result: a cumulative 13.6% drop for the month, with the stock closing at R$ 27.41 on November 10—10% below the price of its July follow-on offering.

What Happened to EGIE3?

Engie Brasil Energia reported its Q3 2026 figures to the market via a filing submitted to CVM on November 10, 2026. Net operating revenue reached R$ 3.670 billion, a 9.8% increase compared to Q3 2025. Adjusted EBITDA reached R$ 1.948 billion, up 4.1% on the same basis. Adjusted net income fell to R$ 716 million, a 2.1% decline from the third quarter of 2025. On an accounting basis—without non-recurring adjustments—net income was R$ 711 million, down 3.7%.

From January to September 2026, the company posted significant year-to-date growth: adjusted EBITDA of R$ 6.372 billion (+10.3%) and revenue of R$ 10.590 billion (+12.2%). However, adjusted net income for the nine-month period grew by just 3.8%, to R$ 2.199 million—a sign that operational expansion is being absorbed by rising financial expenses and depreciation. It is this dynamic that the market is pricing in.

Net operating revenue R$ 3.670 bi

Up 9.8% vs. Q3 2025; long-term contracts and a diversified portfolio supported growth.

Adjusted EBITDA R$ 1.948 bi

Up 4.1%; margin fell from 56.0% to 53.1%, pressured by curtailment and the company's energy hedging strategy.

Adjusted net income R$ 716 mi

Down 2.1% vs. Q3 2025; rising financial expenses and depreciation from newly activated assets consumed EBITDA growth.

Why Did Net Income Fall If EBITDA Rose?

The divergence between growing EBITDA and falling net income has a straightforward explanation: Engie is at the peak of an intense capital expenditure cycle, and the financial cost of this cycle is hitting the income statement. In Q3 2026 alone, the company poured R$ 662 million into new projects. On July 20, the company completed a R$ 2.23 billion payment for the renegotiation of the Public Asset Use (UBP) fee for the Cana Brava and Ponte Pedra hydroelectric plants—a long-standing obligation that matured this quarter and was paid out in a single lump sum. Negative net financial results totaled R$ 614.3 million in Q3 2026, a deterioration of R$ 48 million compared to Q3 2025, reflecting higher debt and elevated interest rates. Combined with increased depreciation on newly activated assets—transmission, solar, and wind projects—costs below EBITDA consumed operational growth. This phenomenon of rising EBITDA alongside falling net income was not isolated this earnings season: Sabesp's (SBSP3) Q3 results followed the exact same pattern, driven by different reasons but sharing the same heavy investment cycle dynamic weighing on net income.

Net debt R$ 25.3 bi
(3.04× EBITDA)
+ Curtailment compressing
generation margin
+ Depreciation of
new assets
= Net income -2.1%
despite EBITDA +4.1%

A positive counterparty in the quarter: on July 17, following General Shareholders' Meeting approval, Engie completed the acquisition of a 40% stake in the Jirau Hydroelectric Power Plant—acquired via an R$ 8.4 billion follow-on offering priced at R$ 30.50 per share, with the issuance of 274 million new shares (a dilution of approximately 19.4% for unitholders who did not participate). With the plant on the balance sheet, it contributed R$ 35 million to EBITDA solely in the post-settlement period—the full impact will begin to show in Q4 2026. Fitch Ratings, reacting to the year's corporate moves, upgraded Engie Brasil's long-term credit rating from BBB- to BBB, with a stable outlook.

The Curtailment Engie Confirmed—and What Lies Ahead in 2027

The forced curtailment of renewable generation by Brazil's grid operator, the ONS, reached 26% in Q3 2026, compared to 23% in the same quarter of 2025. For a company with a heavy portfolio of wind, solar, and small hydroelectric plants—Engie Brasil operates 12,767.3 MW of installed capacity, including 132 MW of complementary renewable sources—curtailment forces the generator to buy energy on the spot market to honor contracts, generally at prices above bilateral agreements. The effect is visible in the net average sales price: R$ 201.77/MWh in the quarter, a 4.7% drop compared to Q3 2025. XP Investimentos, which maintains a Neutral rating on EGIE3 with a price target of R$ 31.40, calculated that the effective price came in 8% below its projections.

The problem is that the outlook does not improve in the short term. Engie itself projects curtailment of 32% across the National Interconnected System for 2027, six percentage points above current levels—a result of excess renewable capacity installed between 2021 and 2024 without equivalent demand growth. The company has publicly stated that it sees no economic conditions to resume greenfield renewable projects in the short to medium term. This stance signals a pause in a revenue growth driver that fueled its recent expansion cycle; for shareholders, it means the 53.1% EBITDA margin—already below historical averages—could compress further over the coming year.

The Off-Balance-Sheet Risk: TAG and the ANP Decision

The Q3 2026 operational results hold predictable contours for anyone following the company. What weighs heaviest on the stock price, according to analysts, lies off the balance sheet: Transportadora Associada de Gás (TAG), in which Engie Brasil holds a stake, is at the center of a regulatory dispute with the ANP (Brazil's oil and gas regulator). The agency wiped out the Regulatory Asset Base (BRA) for the 2026–2030 tariff cycle, arguing that TAG's pipelines—which operate the Northeast Network—have already been 100% amortized and therefore do not entitle the company to remuneration on new capital. TAG challenged the methodology through administrative appeals; the ANP board unanimously rejected them.

The final decision on the Maximum Permitted Revenue for the 2026–2030 cycle has not yet been published, but the consolidated regulatory trend points to a significant reduction in pipeline revenue. The Q3 2026 earnings release explicitly cites this risk as a "point of attention," without quantifying the specific impact on Engie Brasil—since that depends on the company's ownership structure in TAG and the final tariff terms. Facing this uncertainty without precise figures, the market is opting for a precautionary discount.

  • Revenue and EBITDA growing for five consecutive quarters; long-term contracts protect most revenue from spot market volatility
  • Fitch upgraded credit rating from BBB- to BBB; payment of the UBP fee (R$ 2.23 billion) eliminated a long-term uncertainty regarding Cana Brava and Ponte Pedra
  • Integrated Jirau plant adds complementary hydro capacity to the portfolio; full effect begins in Q4 2026
  • Curtailment at 26% in Q3 2026, projected at 32% for 2027; falling net sales price per MWh, EBITDA margin at 53.1%—compressing relative to historical medians
  • Net debt at 3.04× EBITDA, well above the historical median of 2.33×; ROIC fell from 15.1% to 12.9% year-over-year
  • TAG with BRA wiped out by ANP; Maximum Permitted Revenue for 2026–2030 still undefined; outcome could reduce pipeline segment revenue
What This Means for EGIE3 Investors

The stock is trading at R$ 27.41, 10% below July's follow-on price of R$ 30.50. Investors who bought in the follow-on are in the red; those who held shares beforehand and did not participate were diluted by approximately 19%. The comparison between Engie and CPFE3 published this week showed that the discount is already partially priced into multiples: a P/E ratio of 7.9 and an EV/EBITDA of 6.9 sit below historical medians. The dividend yield at the current price reaches approximately 4.1% (based on distributions of R$ 1.12 per share over the last 12 months)—reasonable, but far from what is needed to compete with fixed income while the Selic interest rate remains elevated. The 12-month peak of R$ 39.36 seems distant while curtailment and TAG lack a clearer resolution. Engie Brasil is operationally solid; the problem is that the two risks weighing on the stock—structural and open-ended—lead the market to demand a discount until answers arrive.

What to Watch From Here On

1

TAG tariff review — the ANP still needs to publish the final Maximum Permitted Revenue for the 2026–2030 cycle; if a zero BRA is confirmed in the definitive figure, it will directly impact Engie Brasil's pipeline segment revenue; Q4 2026 earnings will bring the first figures under the new regulatory cycle.

2

2027 curtailment — with the ONS projecting 32%, the net average sales price (R$ 201.77/MWh in Q3 2026) could fall further; the trigger to revise this scenario is a structural shift in energy demand—monitor monthly ONS data and the guidance Engie releases during its earnings conference call on November 11.

3

Dividends and debt — R$ 0.5442 per share was declared for the first half of 2026 (ex-date August 21); with net debt at 3.04× EBITDA, dividend growth depends on Jirau actually contributing in Q4 2026; the stock's complete dividend history allows investors to track whether the post-follow-on distribution policy maintains current yields or pulls back.

4

Full balance-sheet contribution of Jirau — the plant contributed R$ 35 million to EBITDA only in the post-settlement portion of Q3; Q4 2026 will bring the first full quarter with Jirau consolidated (3,750 MW of hydro capacity); if the contribution falls short of expectations given curtailment, the R$ 8.4 billion premium paid for the deal will continue to face market skepticism.